艾沙度林在报告既往使用洛哌丁胺的腹泻型肠易激综合征患者中的疗效
两项3期研究纳入符合罗马III标准的腹泻型肠易激综合征成人患者,随机接受安慰剂或艾沙度林75 mg或100 mg每日两次,疗程26周或52周。在既往使用洛哌丁胺且症状控制不佳的患者中,艾沙度林75 mg和100 mg的复合应答率在1-12周均高于安慰剂,不良事件包括恶心和腹痛。
要点
- 在既往使用洛哌丁胺且症状控制不佳的腹泻型肠易激综合征患者中,艾沙度林75 mg和100 mg的1-12周复合应答率分别为26.3%和27.0%,均高于安慰剂的12.7%。
- 将每日补救性洛哌丁胺使用计为非应答日后,艾沙度林75 mg和100 mg的复合应答率在1-12周和1-26周仍高于安慰剂(P<0.001)。
- 不良事件包括恶心和腹痛。
核心结论
- 艾沙度林可有效且安全地治疗既往使用洛哌丁胺后症状控制充分或不充分的腹泻型肠易激综合征患者的腹痛和腹泻症状,无论治疗期间是否使用洛哌丁胺作为补救药物,疗效和安全性相当。
研究设计与样本
- 两项3期研究纳入符合罗马III标准的腹泻型肠易激综合征成人患者,随机接受安慰剂或艾沙度林75 mg或100 mg每日两次,疗程26周(IBS-3002)或52周(IBS-3001)。
- 共纳入2428例患者,其中36.0%报告既往使用洛哌丁胺,这些患者中61.8%报告既往洛哌丁胺对腹泻型肠易激综合征症状控制不充分。
主要发现
- 在既往使用洛哌丁胺且症状控制不佳的患者中,1-12周复合应答率:艾沙度林75 mg组为26.3%(P=0.001),100 mg组为27.0%(P<0.001),均高于安慰剂组的12.7%。
- 在1-26周观察到相似结果。
- 将每日补救性洛哌丁胺使用计为非应答日后,艾沙度林75 mg和100 mg组在1-12周(P<0.001)和1-26周(P<0.001)的复合应答率仍高于安慰剂组。
- 不良事件包括恶心和腹痛。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success. This analysis evaluated the efficacy of eluxadoline in patients previously treated with loperamide in two phase 3 studies. METHODS: Adults with IBS-D (Rome III criteria) were enrolled and randomized to placebo or eluxadoline (75 or 100 mg) twice daily for 26 (IBS-3002) or 52 (IBS-3001) weeks. Patients reported loperamide use over the previous year and recorded their rescue loperamide use during the studies. The primary efficacy end point was the proportion of patients with a composite response of simultaneous improvement in abdominal pain and reduction in diarrhea. RESULTS: A total of 2,428 patients were enrolled; 36.0% reported prior loperamide use, of whom 61.8% reported prior inadequate IBS-D symptom control with loperamide. Among patients with prior loperamide use, a greater proportion treated with eluxadoline (75 and 100 mg) were composite responders vs. those treated with placebo with inadequate prior symptom control, over weeks 1-12 (26.3% (P=0.001) and 27.0% (P<0.001) vs. 12.7%, respectively); similar results were observed over weeks 1-26. When daily rescue loperamide use was imputed as a nonresponse day, the composite responder rate was still higher in patients receiving eluxadoline (75 and 100 mg) vs. placebo over weeks 1-12 (P<0.001) and weeks 1-26 (P<0.001). Adverse events included nausea and abdominal pain. CONCLUSIONS: Eluxadoline effectively and safely treats IBS-D symptoms of abdominal pain and diarrhea in patients who self-report either adequate or inadequate control of their symptoms with prior loperamide treatment, with comparable efficacy and safety irrespective of the use of loperamide as a rescue medication during eluxadoline treatment.
引用
- Lacy BE, Chey WD, Cash BD, et al. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol. 2017. PMID: 28417992. doi:10.1038/ajg.2017.72
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。